Sat Oct 05 04:03:06 UTC 2024: ## AbbVie (ABBV) Sees Mixed Activity from Institutional Investors, Remains “Buy” Rated

**Chicago, IL (October 5, 2024):** AbbVie Inc. (NYSE:ABBV), a pharmaceutical giant, witnessed varied activity from institutional investors in the recent quarter. While Marotta Asset Management reduced its stake in the company by 2.9%, other hedge funds like Fairway Wealth LLC, Ridgewood Investments LLC, Vermillion & White Wealth Management Group LLC, IFS Advisors LLC, and Redmont Wealth Advisors LLC made new investments in AbbVie.

Despite this mixed sentiment, institutional investors collectively hold 70.23% of AbbVie’s stock, indicating continued confidence in the company.

**Positive Outlook from Analysts:**

Multiple research firms remain optimistic about AbbVie’s future prospects. BMO Capital Markets raised its price target to $214.00, while Cantor Fitzgerald and Piper Sandler Companies reaffirmed “overweight” ratings. Truist Financial and William Blair upgraded AbbVie to “buy” and “strong-buy” ratings, respectively. Overall, AbbVie boasts an average rating of “Buy” and a consensus target price of $191.64, according to MarketBeat.

**Dividend Announcement and Insider Trading:**

AbbVie announced a quarterly dividend of $1.55 per share, payable on November 15th to investors of record on October 15th. This represents a 3.17% dividend yield.

In insider trading news, Chairman Richard A. Gonzalez sold a significant number of shares in recent months, raising questions about his outlook for the company’s future.

**Financial Performance and Key Highlights:**

AbbVie’s stock opened at $195.38 on Friday. The company has a market capitalization of $345.02 billion and boasts a solid financial profile with a price-to-earnings ratio of 57.98, a PEG ratio of 2.65, and a beta of 0.64.

**Conclusion:**

While AbbVie faces some volatility in its investment landscape, analysts remain bullish on the company’s performance. The dividend announcement further strengthens its appeal to income-seeking investors. However, recent insider selling activity warrants close monitoring. Investors should carefully consider all available information before making any investment decisions.

Read More